A useful result needs a timeframe
What weight loss on tirzepatide can tell us
Tirzepatide has strong human evidence for weight loss. The size of that change matters. So do side effects and what happens when treatment stops.
- Goal
- Understand weight treatment
- Measurement
- Body weight over 72 weeks
- Limit
- An average isn't your forecast
One set of numbers worth keeping
In SURMOUNT-1, a manufacturer-funded 72-week tirzepatide trial, average weight loss ranged from about 15% to 21% across treatment groups, compared with about 3% on placebo, a dummy treatment. Participants were adults without diabetes who had obesity, or overweight with a weight-related health problem. Participants also received lifestyle support.
That's a substantial difference. It's also a group average, rather than a prediction for you. The percentage describes body weight lost, not pure fat loss or a measured gain in stamina.
Which medicine, and for what?
Tirzepatide acts on the same cell receptors as two gut hormones involved in appetite and blood sugar. A receptor is a place where a chemical message can act on a cell. The Zepbound (tirzepatide) label describes the approved weight-management use for adults with obesity, or overweight with a weight-related health condition, alongside a reduced-calorie diet and increased physical activity.
Mounjaro (tirzepatide) has a type 2 diabetes use. The ingredient is shared; the approved uses differ. A familiar ingredient name doesn't answer which product or medical purpose is being discussed.
Compounded tirzepatide is not FDA-approved. Approval of Zepbound or Mounjaro doesn't extend to a separately compounded preparation. That product distinction belongs in a treatment conversation too.
Stopping is part of the story
SURMOUNT-4 tested continued tirzepatide against withdrawal in an adult weight-maintenance study. After 36 weeks on tirzepatide, 670 participants who completed that first phase were assigned to continue it or switch to placebo for another 52 weeks. On average, the switch group regained weight; the continuing group lost more.
That comparison starts with people who completed the initial treatment phase. It doesn't describe everyone who might begin treatment, and it doesn't mean everyone regained all the weight they had lost.
That result is a reason to discuss maintenance early. It doesn't mean this page can decide your treatment length. The benefit, side effects and your own history need to be considered together.
Side effects deserve more than fine print
The prescribing information lists nausea, diarrhea, vomiting and constipation among common side effects. Stomach and bowel problems can be severe. Fluid loss can lead to kidney injury; the label also warns about gallbladder problems, inflammation of the pancreas and serious allergic reactions.
The boxed warning concerns thyroid C-cell tumors seen in rats. It's unknown whether people given tirzepatide develop these same tumors. The label rules it out with a personal or family history of medullary thyroid cancer, with the inherited condition MEN 2, or with a previous serious allergy to tirzepatide or its ingredients.
The label doesn't recommend Zepbound for severe gastroparesis, where the stomach empties very slowly. It warns that combining tirzepatide with insulin or medicines that make the body release insulin can raise the risk of low blood sugar. Tirzepatide can also make birth control pills less reliable around starting treatment and dose increases.
The label says weight loss isn't recommended during pregnancy. Upcoming anesthesia or deep sedation matters too: the label warns of stomach contents entering the lungs during these procedures. A licensed U.S. clinician can review those details. The comparison page can help you put the goal into words before that discussion.